Steven P. Fling

10.5k total citations · 2 hit papers
62 papers, 3.4k citations indexed

About

Steven P. Fling is a scholar working on Immunology, Oncology and Epidemiology. According to data from OpenAlex, Steven P. Fling has authored 62 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Immunology, 27 papers in Oncology and 14 papers in Epidemiology. Recurrent topics in Steven P. Fling's work include Immunotherapy and Immune Responses (15 papers), T-cell and B-cell Immunology (14 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Steven P. Fling is often cited by papers focused on Immunotherapy and Immune Responses (15 papers), T-cell and B-cell Immunology (14 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Steven P. Fling collaborates with scholars based in United States, South Africa and Germany. Steven P. Fling's co-authors include Dale S. Gregerson, Donald Pious, B Arp, Leonard D’Amico, Melissa A. Geller, Mary L. Disis, Joseph Beechem, Kunle Odunsi, Patrick Danaher and Lucas Dennis and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Steven P. Fling

57 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea

1986 860 citations Steven P. Fling, Dale S. Gregerson profile →
Gene expression markers of Tumor Infiltrating Leukocytes

2017 478 citations Leonard D’Amico, Mary L. Disis et al. Journal for ImmunoTherapy of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven P. Fling United States	22	1.6k	1.1k	673	556	268	62	3.4k
Jie Wang China	30	1.3k 0.8×	2.1k 2.0×	1.6k 2.4×	518 0.9×	245 0.9×	136	4.7k
Franco M. Buonaguro Italy	34	732 0.5×	1.3k 1.2×	719 1.1×	1.2k 2.1×	202 0.8×	111	3.4k
Young Chul Sung South Korea	37	1.7k 1.1×	1.5k 1.4×	831 1.2×	1.1k 2.0×	349 1.3×	127	4.2k
Uzi Gileadi United Kingdom	33	2.2k 1.4×	1.6k 1.5×	1.2k 1.9×	388 0.7×	249 0.9×	51	4.4k
Xiangyang Xue China	30	591 0.4×	1.8k 1.7×	512 0.8×	407 0.7×	169 0.6×	133	3.2k
Paul W. Dempsey United States	20	3.0k 1.9×	1.3k 1.3×	705 1.0×	461 0.8×	299 1.1×	29	4.4k
Richard Wubbolts Netherlands	35	1.4k 0.9×	3.2k 3.0×	387 0.6×	483 0.9×	329 1.2×	59	5.2k
Annemarthe G. van der Veen United Kingdom	22	1.8k 1.1×	1.9k 1.8×	812 1.2×	453 0.8×	270 1.0×	26	3.7k
Richard L. Friedman United States	20	792 0.5×	854 0.8×	490 0.7×	528 0.9×	450 1.7×	35	3.3k
Xaveer Van Ostade Belgium	27	922 0.6×	1.0k 0.9×	311 0.5×	446 0.8×	101 0.4×	61	2.3k

Countries citing papers authored by Steven P. Fling

Since Specialization

Citations

This map shows the geographic impact of Steven P. Fling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven P. Fling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven P. Fling more than expected).

Fields of papers citing papers by Steven P. Fling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven P. Fling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven P. Fling. The network helps show where Steven P. Fling may publish in the future.

Co-authorship network of co-authors of Steven P. Fling

This figure shows the co-authorship network connecting the top 25 collaborators of Steven P. Fling. A scholar is included among the top collaborators of Steven P. Fling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven P. Fling. Steven P. Fling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ramaswami, Ramya, Angela Shaulov Kask, Leonard D’Amico, et al.. (2025). Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma. Journal for ImmunoTherapy of Cancer. 13(2). e010291–e010291. 2 indexed citations

Ryu, Heeju, Timothy Bi, Thomas H. Pulliam, et al.. (2024). Merkel cell polyomavirus-specific and CD39+CLA+ CD8 T cells as blood-based predictive biomarkers for PD-1 blockade in Merkel cell carcinoma. Cell Reports Medicine. 5(2). 101390–101390. 11 indexed citations

Sweis, Randy F., Gurkamal Chatta, Helen Moon, et al.. (2024). A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer. Clinical Cancer Research. 31(2). 299–307.

Pachynski, Russell K., Gurkamal Chatta, Rohit Jain, et al.. (2023). 2367P A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC). Annals of Oncology. 34. S1204–S1205. 1 indexed citations

Lurain, Kathryn, Ramya Ramaswami, Irene Ekwede, et al.. (2023). 1979P phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS). Annals of Oncology. 34. S1056–S1056. 2 indexed citations

Odeny, Thomas, Kathryn Lurain, Julius Strauss, et al.. (2022). Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. Journal for ImmunoTherapy of Cancer. 10(9). e005128–e005128. 7 indexed citations

Finak, Greg, Leonard D’Amico, Nina Bhardwaj, et al.. (2021). New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy. Patterns. 2(12). 100372–100372. 21 indexed citations

Church, Candice D., Amalie Kai Bentzen, Steven P. Fling, et al.. (2021). 299 Broad T antigen-specific CD8+ T cell repertoire is associated with response to PD-1 blockade in virus positive merkel cell carcinoma. SHILAP Revista de lepidopterología. A322–A322. 2 indexed citations

Barber, Daniel L., Shunsuke Sakai, Ragini R. Kudchadkar, et al.. (2019). Tuberculosis following PD-1 blockade for cancer immunotherapy. Science Translational Medicine. 11(475). 132 indexed citations

10.

Margolin, Kim, Chihiro Morishima, Vamsidhar Velcheti, et al.. (2018). Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 24(22). 5552–5561. 146 indexed citations

11.

Miller, Natalie, Candice D. Church, Steven P. Fling, et al.. (2018). Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. Journal for ImmunoTherapy of Cancer. 6(1). 131–131. 27 indexed citations

12.

Morishima, Chihiro, Douglas G. McNeel, Manish R. Patel, et al.. (2015). CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells. Journal for ImmunoTherapy of Cancer. 3(S2). 1 indexed citations

13.

Gervassi, Ana, Kenneth H. Grabstein, Peter Probst, et al.. (2004). Human CD8+ T Cells Recognize the 60-kDa Cysteine-Rich Outer Membrane Protein from Chlamydia trachomatis. The Journal of Immunology. 173(11). 6905–6913. 27 indexed citations

14.

Starnbach, Michael N., et al.. (2003). An Inclusion Membrane Protein from Chlamydia trachomatis Enters the MHC Class I Pathway and Stimulates a CD8+ T Cell Response. The Journal of Immunology. 171(9). 4742–4749. 90 indexed citations

15.

Gold, Marielle C., Michael W. Munks, Markus Wagner, et al.. (2002). The Murine Cytomegalovirus Immunomodulatory Gene m152 Prevents Recognition of Infected Cells by M45-Specific CTL But Does Not Alter the Immunodominance of the M45-Specific CD8 T Cell Response In Vivo. The Journal of Immunology. 169(1). 359–365. 85 indexed citations

16.

Lewinsohn, David, Liqing Zhu, Davin C. Dillon, et al.. (2001). Classically Restricted Human CD8+ T Lymphocytes Derived from Mycobacterium tuberculosis -Infected Cells: Definition of Antigenic Specificity. The Journal of Immunology. 166(1). 439–446. 83 indexed citations

17.

Coler, Rhea N., Antonio Campos‐Neto, Pamela J. Ovendale, et al.. (2001). Vaccination with the T Cell Antigen Mtb 8.4 Protects Against Challenge with Mycobacterium tuberculosis. The Journal of Immunology. 166(10). 6227–6235. 80 indexed citations

18.

Fling, Steven P., et al.. (1997). Differential APC Requirements of Self- and Nonself-Reactive T Cells and T Cell Hybridomas Specific for Retinal S-Antigen. Journal of Autoimmunity. 10(1). 1–9. 4 indexed citations

19.

Fling, Steven P., et al.. (1995). A radiosensitive APC activity dissociates IL-2 secretion and activation-induced cell death by autoreactive T cell hybridomas. International Immunology. 7(11). 1787–1798. 4 indexed citations

20.

Knospe, Volker, Steven P. Fling, & Dale S. Gregerson. (1988). Assignment of several epitopes to cyanogen bromide peptides of bovine retinal S-antigen by immunoblotting with peptide-specific antibodies. Current Eye Research. 7(2). 181–189. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact